Arizona State and Motorola Collaborate On Applied NanoBioscience Center
Arizona State University and Motorola are creating the Applied NanoBioscience Center, the university said last week. Motorola will provide capital equipment - the remains of its CodeLink products that it sold to Amersham in July - and space that will allow the center to begin operations immediately. The ANBC will become part of ASU’s Arizona Biodesign Institute. The center will eventually be housed in ASU’s first biodesign building, which is expected to be under construction by spring 2003 and occupied by fall 2004. The equipment is what remains of the CodeLink effort products that were sold to Amersham. Additionally, principal investigator Chia-Fu Chou and six other former Motorola researchers will join the center.
UNC-Greensboro Launches Eco-Genomix To Commercialize Microarray Tech
The University of North Carolina-Greensboro said last week that it will launch a company, Eco-Genomix, based on DNA microarray technology that will be commercialized under the product name, “Waterchip.” The product will be used to analyze water, and develops out of gene expression research conducted by biology professor Parke Rublee on the toxic dinoflagellate Pfiesteria piscicida as the cause of massive fish kills in North Carolina’s Albemarle-Pamlico Sound and elsewhere in the US.
Acacia Approves CombiMatrix Tracker
Shareholders last week approved the division of Acacia Research stock into two classes to track the business of Acacia Research and subsidiary CombiMatrix. CombiMatrix, based in Mukilteo, Wash., will trade on the Nasdaq exchange as CBMX while Acacia Research, which produces V-chip technology for television manufacturers, will trade under ACTG. Acacia Research shareholders will receive 0.56 of a share of CombiMatrix stock and one share of Acacia Technology stocks for each share of Acacia Research that they own.
Enzo Posts $17.4M in Q1 Revenue and Income
Enzo Biochem, which makes reagents for microarrays and other consumables, this week reported first-quarter revenue growth atop an increase in R&D spending and a jump in net income. However, a top executive hinted the results were largely due to “unusually strong” — yet short-lived — demand. Total revenue for the period ended Oct. 31 was $17.4 million, compared with $13.4 million one year ago, and R&D spending grew almost 34 percent, to $1.8 million. Enzo posted first quarter net income of $3.7 million, compared with $1.8 million, year over year. The company said it had roughly $73.2 million in cash and cash equivalents as of Oct. 31.
China Scientist Map Indica Genome
Zhu Zuoyan of the Chinese Academy of Sciences (CAS) said last week that scientists in the CAS Genomics and Bioinformatics Institute have completed a detailed map of 97 percent (60,000 genes) of the indica rice genome, according to a report in the People’s Daily of Beijing last week. Earlier this year, the Beijing Genomics Institute of the Chinese Academy of Sciences said it would provide a rice microarray based on the 54,000-gene indica genome published earlier this year.
Incyte Genomics to change its name, Again
Incyte Genomics, which changed its name to Incyte Genomics from Incyte Pharmaceuticals two years ago, will change its name to Incyte Corp., the company said this week. The change reflects a “broader mission,” the company said.
Jeremy Squire Receives Canadian Grant
Jeremy Squire of the Ontario Cancer Institute will receive CA $450,840 ($289,000) for microarray-based research to design new types of chemotherapy for ovarian cancer as part of funding from the Ontario government to the Ontario Cancer Research Network, the government announced last week.
Spotfire Licenses DecisionSite to ArQule
Spotfire of Somerville, Mass., said this week that ArQule of Woburn, Mass., has licensed its DecisionSite for Lead Discovery analysis software.
Roche to Purchase GeneExpress Data
Gene Logic said last week that it has licensed GeneExpress data to Roche. Financial details were not disclosed.
Nanogen Licenses Canavan Disease Info
Nanogen announced last week a non-exclusive license to gene mutation information on Canavan disease from Miami Children’s Hospital Research Institute. Financial terms were not disclosed.